Effects of dapaglifloziN Therapy on myocardial perfusion Reserve in prediabetic patients with stable coronarY artery disease

Asan Medical Center0 个研究点目标入组 60 人开始时间: 待定最近更新: 2022年10月24日

试验速览

暂无简介。

•1) Men or women at least 18 years of age
•2)Prediabetes by ADA criteria (fasting glucose 100-125mg/dl, or HbA1C 5.7-6.4% )(3)
•3)Stable coronary artery disease
•4)Global myocardial perfusion reserve (MPR) index < 2.0
•5)The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

•1) Contraindications to dapapagliflozin
•2) Significant renal disease manifested by creatinine clearance of(eGFR<30 ml/min/1.73m2
•3) Unstable or rapidly progressing renal disease
•4) Acute coronary syndrome, or any other major cardiovascular events within the previous 6 months
•5) Stent placement, or coronary artery bypass graft surgery within the previous 6 months
•6) Planned revascularization within 6 months
•7) Significant disease (diameter stenosis >70% by coronary CT angiography) in major epicardial coronary arteries
•8) Heart failure requiring loop diuretics
•9) Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 3 times upper limit of normal).
•10) Contraindication to adenosine stress test*
•11) Current treatment for the active cancer
•12) Women of child bearing potential who are not willing to use a medically accepted method of contraception. Patient’s pregnancy confirmed by positive pregnancy test, or breast-feeding.
•13) Expected life expectancy < 1 year
•14) Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests which, in the judgment of the investigator, would preclude safe completion of the study.
•15) Unwillingness or inability to comply with the procedures described in this protocol.

发起方